Kythera (KYTH) 2nd-Half NDA on Track, Says FBR Capital
Tweet
Share
E-mailGet Alerts KYTH Hot Sheet
Price: $74.98 --0%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
FBR Capital analyst William Tanner, Ph.D. reiterated an Outperform rating and $68 price target on Kythera Biopharmaceuticals (NASDAQ: KYTH) following Q4 results, saying U.S. NDA is on track for the second quarter.
Tanner said, "We maintain our belief that ATX-101 is a product with significant commercial potential, given the non-invasive nature and sizable population of candidates for submental fat reduction. KYTHERA remains on track to submit an NDA with the FDA before the end of 2Q14 and looks to 2Q15 for a possible approval, with product launch to follow.We believe broad industry interest in aesthetic assets should keep KYTHERA on the dashboard of product consolidators, especially in the current market for late-stage products."
For an analyst ratings summary and ratings history on Kythera Biopharmaceuticals click here. For more ratings news on Kythera Biopharmaceuticals click here.
Shares of Kythera Biopharmaceuticals closed at $46.13 yesterday.
Tanner said, "We maintain our belief that ATX-101 is a product with significant commercial potential, given the non-invasive nature and sizable population of candidates for submental fat reduction. KYTHERA remains on track to submit an NDA with the FDA before the end of 2Q14 and looks to 2Q15 for a possible approval, with product launch to follow.We believe broad industry interest in aesthetic assets should keep KYTHERA on the dashboard of product consolidators, especially in the current market for late-stage products."
For an analyst ratings summary and ratings history on Kythera Biopharmaceuticals click here. For more ratings news on Kythera Biopharmaceuticals click here.
Shares of Kythera Biopharmaceuticals closed at $46.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- Premier Financial Corp. (PFC) PT Lowered to $23 at Keefe, Bruyette & Woods
- RBB Bancorp (RBB) PT Raised to $22 at Keefe, Bruyette & Woods
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
